Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.WT | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by jojomarchon Jan 09, 2020 8:42am

121 Views

Post# 30533740

RE:RE:RE:RE:What could move share price upward?

LaserStock29 wrote:

Longholder99 wrote: They are getting shareholder pressure obviously here and on Twitter to produce something. I can see how people want the short quick cash of a quick double in SP. I'm of the mind that while I'd like to see a short term bump as much as anyone....all it's going to do is make my trading screen look greener. My SP goal is far down the road with this company (100x current price). So whatever they do in the next few months means little to me as long as they are moving forward.

Well Longholder99.... far down the road started in June 2014 for me.. and we have absolutely zero pps uptick....

I think 5 year holding is good enough to say hey we should be trading at $1.25 CAD at a minimum..

This lines up with Rogers 2014 Phase 1 160m Phase 2 360m Phase 3 900-1b from Cambridge via partnerships.

That's why the first 5-6 validate the Phase 1b trial..... because it unlocks a pps valuation so we can finally win here a bit.

Im tired of the scam attitude here that wants to keep the pps at .30 forever

Largest Single Asset deal for China

Review on PDT in Lung Cancer

In the past 10 years, a total of 493 patients participated in prospective clinical studies that evaluated and validated the benefit of PDT, with different photosensitizers, in the treatment of early-stage (n = 370) and advanced (n=123) NSCLC as detailed in Tables 1 and and2.2. The complete response for early-stage disease ranged from 72% to an impressive 94% and 100% (Table 1). In the case of advanced disease, the range of local control and partial response was reported to vary from 78 to 100%, respectively (Table 2).

Taking from the LaserStock research

Cheers

Bullboard Posts

How a junior advances one of the largest undeveloped diamond projects